Amgen Inc. (AMGN) Q3 2026 (USD): Adj. EPS 6.45 (exp. 5.79), Revenue 10.4bln (exp. 10.07bln), Adj. operating income 4.7bln (exp. 4.33bln)

• FY revenue 38.9-39.7bln (exp. 39bln).
• FY adj. EPS 22.90-23.70 (exp. 23.06).

A clean beat across all three headline lines with FY guidance raised or held above consensus on both revenue and EPS is the stronger of the two common large-cap pharma print patterns; the weaker variant is a quarterly beat paired with a trimmed or merely reaffirmed guide, which historically fades faster. The size of the EPS beat relative to the revenue beat points to margin and mix doing the work rather than topline acceleration, which in this sector usually invites scrutiny of how much is operating leverage versus items below the line such as tax rate or buybacks. For a large diversified biotech the follow-through questions tend to be franchise-specific: growth-driver trajectory against patent-cliff exposure on the mature portfolio, pipeline updates on the call, and whether buy-side whisper numbers sat above the published consensus, which determines whether an above-consensus print still disappoints the positioning. Initial reaction in names of this profile has tended to be decided less by the headline beats than by the guidance midpoint versus where the street's models were already drifting, and by commentary on LOE erosion and pipeline spend. The call is where these prints typically get re-rated either way.